KALA BIO
KALA
14 hedge funds and large institutions have $1.06M invested in KALA BIO in 2026 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 18 closing their positions.
600% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 1
261% more capital invested
Capital invested by funds: $294K → $1.06M (+$766K)
3.29% more ownership
Funds ownership: 0% → 3.3% (+3.3%)
50% less funds holding
Funds holding: 28 → 14 (-14)
78% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$1.06M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$679K |
| 3 |
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
|
+$489K |
| 4 |
BlackRock
New York
|
+$346K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$201K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$72.3K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$48.8K |
| 3 |
VF
Virtu Financial
New York
|
-$26K |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$24.5K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$15K |
KALA Hedge Fund Activity: Q2 2026 in Review
14 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in KALA BIO (KALA) for Q2 2026, worth a combined $1.06M — up 261% from $294K a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of KALA and 4 opened new positions — a net loss of 14 holders — while 1 trimmed existing stakes and 7 added.
The largest buyer was Vanguard Capital Management, adding an estimated $1.06M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $72.3K sold.
- 14 institutional investors held KALA BIO (KALA) as of Q2 2026, down from 28 in Q1 2026.
- Funds reported $1.06M of KALA BIO stock for Q2 2026, up 261% quarter-over-quarter.
- 4 funds opened new KALA BIO positions in Q2 2026 and 18 closed out, a net change of -14 holders.
- The largest KALA BIO buyer in Q2 2026 was Vanguard Capital Management, an estimated $1.06M added.
- The largest KALA BIO seller in Q2 2026 was Renaissance Technologies, an estimated $72.3K sold.
Based on aggregated 13F filings for Q2 2026.